TARS
Tarsus Pharmaceuticals, Inc.NASDAQHealthcare$70.12-0.14%ClosedMarket Cap: $2.98B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
8.74
P/S
6.62
EV/EBITDA
-51.85
DCF Value
$-418.84
FCF Yield
-0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.6%
Operating Margin
-15.7%
Net Margin
-14.7%
ROE
-19.6%
ROA
-11.8%
ROIC
-16.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $151.7M | 92.8% | $-8.0M | $-8.4M | $-0.20 | — |
| FY 2025 | $451.4M | 93.2% | $-71.0M | $-66.4M | $-1.59 | — |
| Q3 2025 | $118.7M | 79.3% | $-14.5M | $-12.6M | $-0.30 | — |
| Q2 2025 | $102.7M | 93.9% | $-22.2M | $-20.3M | $-0.48 | — |
| Q1 2025 | $78.3M | 93.3% | $-26.3M | $-25.1M | $-0.64 | — |
| Q4 2024 | $66.4M | 92.6% | $-24.4M | $-23.1M | $-0.60 | — |
| FY 2024 | $183.0M | 93.0% | $-120.6M | $-115.6M | $-3.07 | — |
| Q3 2024 | $48.1M | 93.3% | $-25.2M | $-23.4M | $-0.61 | — |
| Q2 2024 | $40.8M | 92.6% | $-33.3M | $-33.3M | $-0.88 | — |
| Q1 2024 | $27.6M | 94.0% | $-37.7M | $-35.7M | $-1.01 | — |
| Q4 2023 | $13.1M | 90.7% | $-44.5M | $-41.9M | $-1.31 | — |
| FY 2023 | $17.4M | 90.9% | $-143.2M | $-135.9M | $-4.62 | — |